Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon

Reuters

06-16

Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon

Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039814) on June 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543672868"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543672868\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543672868?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543672868","market":"us","top_or_hot":-1,"title":"Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039814) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAinos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039814) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIMD","symbol_name":"AINOS Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL6P7mrc:1","article_id":"2543672868","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543672868","pubTimestamp":1750075250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjgren's syndrome . This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 16, 2025, and is solely responsi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIMD":"AINOS Inc.","BK4139":"生物科技"},"translate_title":"Ainos Inc.获得台湾监管机构批准开始VELDONA人体试验®口服干扰素","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIMD":0.9},"content_text":"Ainos Inc. Receives Regulatory Approval in Taiwan to Begin Human Trials for VELDONA® Oral Interferon\n    \n\n        Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039814) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}